Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-IPF Phase 2a trial continue without modification
Interim 12-week data expected in early 2023
https://www.biospace.com/article/releases/pliant-therapeutics-announces-positive-dsmb-safety-review-of-integris-ipf-phase-2a-trial-of-pln-74809-at-320-mg-dose-in-idiopathic-pulmonary-fibrosis/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.